Document:

EX-4.7

  Exhibit 4.7 

 
  
  

			
	 ALAMOS GOLD INC.

TREASURY OFFERING OF COMMON SHARES
	  	January 25, 2017

  
  

An amended and restated preliminary short form prospectus containing important information relating to the securities described in this
document has not yet been filed with the securities regulatory authorities in each of the provinces and territories of Canada. A copy of the amended and restated preliminary short form prospectus is required to be delivered to any investor that
received this document and expressed an interest in acquiring the securities. 
 There will not be any sale or any acceptance of an
offer to buy the securities until a receipt for the final short form prospectus has been issued. 
 This document does not provide
full disclosure of all material facts relating to the securities offered. Investors should read the amended and restated preliminary short form prospectus, final short form prospectus and any amendment, for disclosure of those facts, especially risk
factors relating to the securities offered, before making an investment decision. 
  

			
	ISSUER:	  	 Alamos Gold Inc. (“Alamos” or the “Company”)

		
	AMOUNT:	  	 US$250,027,500

		
	ISSUE:	  	 Treasury offering of 31.450,000 common shares of the Company (the “Common Shares”).

		
	ISSUE PRICE:	  	 US$7.95 per Common Share

		
	OVER-ALLOTMENT OPTION:	  	 The Company has granted the Underwriters an option, exercisable at the Issue Price at any time up to 30 days following the
closing of the offering, to purchase up to an additional 15% of the offering to cover over-allotments, if any.

		
	USE OF PROCEEDS:	  	 The Company intends to use the net proceeds of the offering and existing cash to repay all of its outstanding US$315
million senior unsecured 7.75% high yield notes maturing 2020.

		
	LISTING:	  	 Application will be made to list the Common Shares on the Toronto Stock Exchange (the “TSX”) and on the New York
Stock Exchange (the “NYSE”). Listing will be subject to fulfilling all the listing requirements of the TSX and NYSE, respectively. The existing common shares of the Company are listed on the TSX and NYSE under the symbol
“AGI”.

		
	FORM OF OFFERING:	  	 Public offering in all provinces and territories of Canada (excluding Quebec) by way of a short form prospectus and in the
United States pursuant to a registration statement filed under the Multi-Jurisdictional Disclosure System and internationally as expressly permitted by the Company.

		
	FORM OF UNDERWRITING:	  	 Bought deal, subject to syndication, and subject to a mutually acceptable underwriting agreement containing “disaster
out”, “regulatory out” and “material adverse change out” clauses running to Closing.

		
	ELIGIBILITY:	  	 Eligible for RRSPs, RRIFs, RESPs, TFSAs, RDSPs and DPSPs.

		
	BOOKRUNNERS:	  	 TD Securities Inc., BMO Capital Markets and Macquarie Capital Markets Canada Ltd.

		
	UNDERWRITING FEE:	  	 4.00%

		
	CLOSING:	  	 February 9, 2017

 The Company has filed a registration statement (including a prospectus) with the United States Securities and Exchange
Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information
about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the
prospectus if you may request it from TD Securities Inc. in Canada, Attention: Symcor, NPM (tel: 289-360-2009, email: sdcconfirms@td.com), 1625 Tech Avenue, Mississauga ON L4W 5P5; or from TD Securities (USA) LLC in the United States. (tel:
212-827-7392), 31 W 52nd Street, New York NY 10019 or from Macquarie Capital Markets Canada Ltd. in Canada,,email: linda.lang@macquarie.com; or from Macquarie Capital Markets North America Ltd., email,linda.lang@macquarie.com.EXHIBIT 10.27

 

		
        Health
        Discovery Corporation

        4243 Dunwoody Club Drive, Suite 202

        Atlanta, Georgia 30350

        (678) 336-5300
	 

 

	January 23, 2017	VIA EMAIL

 

Douglas M. VanOort

Chairman and Chief Executive Officer

NeoGenomics Laboratories,
Inc.

12701 Commonwealth Drive

Suite 9

Fort Myers, Florida 33913

 

Mr. VanOort:

 

Health Discovery Corporation (“HDC”)
has previously requested a complete statement of any and all uses of any kind of HDC technology by NeoGenomics Laboratories, Inc.
(“NEO”) as required by the Master License Agreement (“MLA”) dated January 6, 2012. The MLA includes a provision
(Section 3.7) for NEO to provide such reporting on a timely and complete basis. To date, NEO has ignored this requirement and several
requests by HDC for the required information as called for in the MLA. HDC repeats its demand for such a statement and accounting
for any and all uses of HDC technology by NEO within 4 business days.

 

In the absence of NEO providing this information,
HDC has prepared an invoice, which is enclosed. This invoice is based on HDC’s good faith analysis of information it believes
to be accurate for amounts currently owed to HDC as compensation for the revenue received for the use of HDC’s technology
by NEO to date. HDC hereby demands immediate payment of $2,280,000. The invoice is based on amounts owed as far back as April 2016
so these amounts owed are well beyond past due. Additionally, as further details are discovered, HDC reserves the right to increase
the amount of this invoice.

 

It should also be noted that on January 9,
2017, HDC requested information pertaining to NEO’s assertion that NEO had a First Commercial Use (“Commercial Use”)
of a Flow Cytometry Interpretation System based product or service. Because NEO did not provide the information requested, HDC
hereby rejects NEO’s claim of Commercial Use.

 

We remind you of HDC’s notice to NEO
dated October 3, 2016 in which HDC elected its right to cancel all licenses that are the subject of the MLA. HDC subsequently delayed
the effectiveness of the October 3, 2016 letter. The purpose of the delay was to allow for a discussion between the parties to
find alternative remedies for HDC. After the passage of over one hundred days and one formal meeting in New York without any resolution,
HDC’s board has determined that the best interest of its shareholders is to take the following action. Therefore, you are
advised that HDC hereby declares its letter of October 3, 2016 effective immediately. Accordingly, HDC exercises its right pursuant
to Section 8.3 in the agreement to terminate all of the licenses that are the subject of the MLA.

 

    	 	 

     

    

 

As stated in our October 3, 2016 letter, the
principal basis for the termination of the licenses is NEO’s failure to perform its obligations as set forth in Section 2.3.
Specifically, NEO agreed to use its best efforts to develop the Initial Licensed Products and have a First Commercial Use of such
licensed products within the Development Term. The Development Term commenced on January 6, 2012 and ended on January 7, 2014.
Since the Development Term ended on January 7, 2014, there is no cure period.

 

The facts cited in the fourth paragraph of
the October 3, 2016 letter remain accurate but there have been subsequent developments that are very concerning to HDC.

 

During an October 26, 2016 earnings conference
call with investors and investment analysts, Mr. Steve Jones made detrimental and revealing statements concerning HDC. Mr. Jones
stated that NEO intends to commercialize a prostate test but that NEO alleges the test is not based on HDC technology. HDC asserts
that this statement is untrue. In fact, NEO’s publications related to the test, NeoLAB Prostate, clearly indicate the use
of HDC’s know-how and technology including, but not limited to, the four genes that are a part of a pending patent with the
United States Patent and Trademark Office. These same genes are part of a patent issued in Europe, which does not expire until
December 2029. Therefore, NEO’s statements on October 26, 2016 are untrue and possibly deceptive. In addition, the statement
was clearly damaging to HDC and its shareholders. The statement was injurious to the public reputation of HDC and its technology.

 

Equally concerning, however, is that the statement
is an admission by NEO that it not only confirms it failed to fulfill its best efforts obligation to HDC but that NEO has actually
been undertaking to surreptitiously develop a product which would directly compete with an HDC based product for some currently
unknown period of time. Through numerous public statements over the years, NEO led HDC and its shareholders to believe that it
was using its best efforts to develop and commercialize a prostate test based upon HDC technology as it had agreed to do. In fact,
it was doing no such thing and it was secretly developing a competitive product. Mr. VanOort also noted this unsettling development
during a conference call with HDC on October 5, 2016. You stated that NEO was not using HDC technology in its prostate test and
that NEO, therefore, had no obligation to pay any milestone and royalties to HDC. You admitted that HDC had “pointed us in
the right direction” and that NEO would consider paying a greatly reduced compensation on the condition that HDC agree to
accept a renegotiation of the MLA on terms and conditions materially adverse to HDC.

 

It is clear that HDC and its shareholders have
been damaged by the actions, inactions and false statements made by NEO. HDC is evaluating such damages and intends to seek professional
advice as to the nature and extent of such damages and appropriate actions that HDC should take in order to protect its shareholders.

 

To date, HDC’s analysis of such damages
includes, but is not limited to, the following:

 

		1)	Damages sustained as a result of NEO’s failure to use its best efforts to develop and commercialize
HDC technology in the agreed upon time frame.

 

		2)	NEO’s failure as above precluded HDC from the opportunity to contract with other parties
to develop and commercialize HDC’s technology thereby foregoing substantial value that would have accrued from timely development
of a product or service based on HDC technology.

 

		3)	Damage to HDC’s reputation for its technology, which may impair HDCs ability to find other
development partners for its technology.

 

		4)	Damage sustained by HDC’s past and current shareholders.

 

    	 	 

     

    

 

HDC hereby demands that NEO immediately cease
and desist from the use of any HDC technology in any way, including but not limited to, any use or sale of any product / service
or combination product / service which is based on or uses any HDC technology or intellectual property.

 

Finally, please be notified that any patents
that NEO has or will apply for as well as any patents that are issued which are based in whole or in part on HDC’s patents
may not be used in the absence of a license agreement between NEO and HDC.

 

If you have any questions please call either
of the HDC representatives listed in the January 9, 2017 letter to NEO.

 

Sincerely,

 

/s/ Board of Directors

Health Discovery Corporation

 

Enclosure

 

Cc: Mr. Daniel Nunn,
Nelson Mullins Riley & Scarborough LLP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]